Skinvisible (SKVI) Common Equity (2010 - 2026)

Skinvisible has disclosed Common Equity across 17 years of filings, most recently posting -$10.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$10.5 million, down 11.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.5 million (down 11.08% YoY), and the FY2025 annual result was -$10.3 million, down 11.27% from the prior year.
• Common Equity came in at -$10.5 million for Q1 2026 at Skinvisible, down from -$10.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$5.6 million in Q1 2022 to a low of -$10.5 million in Q1 2026.
• The 5-year median for Common Equity is -$9.2 million (2024), against an average of -$8.6 million.
• Across the five-year window, Common Equity tumbled 44.85% in 2023 and retreated 1.39% in 2025, its largest moves.
• Skinvisible's Common Equity stood at -$6.6 million in 2022, then slumped by 35.88% to -$9.0 million in 2023, then decreased by 2.22% to -$9.2 million in 2024, then declined by 11.27% to -$10.3 million in 2025, then retreated by 2.6% to -$10.5 million in 2026.
• The last three Common Equity figures came in at -$10.5 million (Q1 2026), -$10.3 million (Q4 2025), and -$10.0 million (Q3 2025), per Business Quant data.